Evocalcet Explained

Iupac Name:	2-[4-[(3''S'')-3-[[(1''R'')-1-Naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]acetic acid
Width:	200px
Tradename:	Orkedia
Cas Number:	870964-67-3
Atc Prefix:	H05
Atc Suffix:	BX06
Pubchem:	71242808
Drugbank:	DB12388
Unii:	E58MLH082P
Kegg:	D11063
C:	24
H:	26
N:	2
O:	2

Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.^[1] It acts as a calcium-sensing receptor agonist.^[2]

In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.^[3]

Notes and References

1. Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M . 6 . A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro . PLOS ONE . 13 . 4 . e0195316 . 2018 . 29614098 . 5882164 . 10.1371/journal.pone.0195316 . 2018PLoSO..1395316K . free .
2. Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, Kuroda M, Hisada Y, Yanagida T, Yoneda H, Tsukumo Y, Tokunaga S, Kawata T, Ohashi R, Fukuda H, Kojima K, Kannami A, Kifuji T, Sato N, Idei A, Iguchi T, Sakairi T, Moritani Y . 6 . Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism . Bioorganic & Medicinal Chemistry Letters . 28 . 11 . 2055–2060 . June 2018 . 29724589 . 10.1016/j.bmcl.2018.04.055 . free .
3. Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan . May 22, 2018 . Kyowa Hakko Kirin.